EGFR

Across TCGA pan-cancer cohorts, EGFR mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EGFR data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EGFR mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EGFR expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LUAD are the cancer types where EGFR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.568	0.880	<.001	103	view →
PDAC	DFS	Quartile	All	0.260	0.497	.001	50	view →
LUAD	DFS	Median	All	0.866	0.931	.012	11	view →
GBM	DFS	Median	All	0.249	0.499	.006	10	view →
LSCC	OS	Median	II,III,IV	0.798	0.920	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EGFR–CCRCC (DFS)

Open the CCRCC breakdown →